Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Author:

Champiat S.,Lambotte O.,Barreau E.,Belkhir R.,Berdelou A.,Carbonnel F.,Cauquil C.,Chanson P.,Collins M.,Durrbach A.,Ederhy S.,Feuillet S.,François H.,Lazarovici J.,Le Pavec J.,De Martin E.,Mateus C.,Michot J.-M.,Samuel D.,Soria J.-C.,Robert C.,Eggermont A.,Marabelle A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference88 articles.

1. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209 – 032. ASCO 2015;Antonia;J Clin Oncol,2015

2. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

3. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. ASCO 2015;Plimack;J Clin Oncol,2015

4. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. ASCO 2015;Seiwert;J Clin Oncol,2015

5. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. ASCO 2015;Segal;J Clin Oncol,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3